229 related articles for article (PubMed ID: 2550133)
41. Total and split renal function in patients with renovascular hypertension: effects of angiotensin-converting enzyme inhibition.
Reams GP; Singh A; Logan KW; Holmes RA; Bauer JH
J Clin Hypertens; 1987 Jun; 3(2):153-63. PubMed ID: 3039075
[TBL] [Abstract][Full Text] [Related]
42. [Age dependence of the response of blood pressure, heart rate and plasma renin activity to captopril in essential hypertension].
Stanek B; Silberbauer K
Acta Med Austriaca; 1984; 11(3-4):101-5. PubMed ID: 6089491
[TBL] [Abstract][Full Text] [Related]
43. Renal kallikrein-kinin system and the depressor effect of angiotensin converting enzyme inhibitors MK 421, SA 446, and captopril in rats.
Yasujima M; Abe K; Kasai Y; Tanno M; Tajima J; Seino M; Chiba S; Sato K; Goto T; Omata K
Clin Exp Hypertens A; 1984; 6(6):1207-25. PubMed ID: 6086184
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the effect of an angiotensin-converting enzyme inhibitor, alacepril, on drug-induced renin-angiotensin-aldosterone system activation in normal dogs.
Sakatani A; Miyagawa Y; Takemura N
J Vet Cardiol; 2016 Sep; 18(3):248-254. PubMed ID: 27364087
[TBL] [Abstract][Full Text] [Related]
45. [Captopril in the treatment of essential hypertension (author's transl)].
Lederle RM; Klaus D; Braun B
Dtsch Med Wochenschr; 1980 Sep; 105(38):1307-12. PubMed ID: 6257467
[TBL] [Abstract][Full Text] [Related]
46. In vivo comparison of three orally active inhibitors of angiotensin-converting enzyme.
DiNicolantonio R; Dinicolantonio R; Hutchinson JS; Mendelsohn FA; Doyle AE
Am J Cardiol; 1982 Apr; 49(6):1502-4. PubMed ID: 6280478
[TBL] [Abstract][Full Text] [Related]
47. Humoral and hemodynamic effects of increasing doses of captopril in patients with essential hypertension.
Sassano P; Pedrinelli R; Magagna A; Abdel-Haq B; Salvetti A
Am J Cardiol; 1982 Apr; 49(6):1574-6. PubMed ID: 6280486
[TBL] [Abstract][Full Text] [Related]
48. Comparisons of long-term effects between converting enzyme inhibitors and conventional therapy in treating mild to moderate hypertension.
Lin M; Chiang HT; Chen CY
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Nov; 48(5):339-50. PubMed ID: 1659934
[TBL] [Abstract][Full Text] [Related]
49. Effect of alacepril on 24-hour blood pressure in elderly hypertensive patients.
Kohara K; Hara-Nakamura N; Takada Y; Iwata T; Ochi T; Kukita H; Muneta S; Hiwada K
Int J Clin Pharmacol Ther; 1996 Sep; 34(9):380-3. PubMed ID: 8880286
[TBL] [Abstract][Full Text] [Related]
50. Hormonal responses to long-term converting enzyme inhibition in hypertensive patients.
Ogihara T; Maruyama A; Hata T; Mikami H; Nakamaru M; Naka T; Ohde H; Kumahara Y
Clin Pharmacol Ther; 1981 Sep; 30(3):328-35. PubMed ID: 6268347
[TBL] [Abstract][Full Text] [Related]
51. [Treatment of latent diabetic nephropathy with ACE inhibitor alacepril].
Hashimoto T
Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):549-56. PubMed ID: 1920934
[TBL] [Abstract][Full Text] [Related]
52. Abnormal glomerular and tubular function during angiotensin converting enzyme inhibition in renovascular hypertension evaluated by the lithium clearance method.
Pedersen EB; Sørensen SS; Amdisen A; Danielsen H; Eiskjaer H; Hansen HH; Jensen FT; Jespersen B; Madsen B; Nielsen HK
Eur J Clin Invest; 1989 Apr; 19(2):135-41. PubMed ID: 2499471
[TBL] [Abstract][Full Text] [Related]
53. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.
Waeber B; Brunner HR; Brunner DB; Curtet AL; Turini GA; Gavras H
Hypertension; 1980; 2(2):236-42. PubMed ID: 6247269
[TBL] [Abstract][Full Text] [Related]
54. Zinc, angiotensin I-converting enzyme and hypertension.
Lockett CJ; Reyes AJ; Leary WP; Alcocer L; Olhaberry JV
S Afr Med J; 1983 Dec; 64(26):1022-4. PubMed ID: 6316570
[TBL] [Abstract][Full Text] [Related]
55. Converting enzyme inhibition with captopril in patients with primary hyperaldosteronism.
Luderer JR; Demers LM; Harrison TS; Hayes AH
Clin Pharmacol Ther; 1982 Mar; 31(3):305-11. PubMed ID: 6277545
[TBL] [Abstract][Full Text] [Related]
56. Effect of alacepril on blood pressure and neurohumoral factors at rest and during dynamic exercise in patients with essential hypertension.
Kinugawa T; Kitamura H; Ogino K; Noguchi N; Matsumoto T; Hisatome I; Miyakoda H; Kotake H; Mashiba H
Br J Clin Pharmacol; 1992 Oct; 34(4):366-9. PubMed ID: 1457272
[TBL] [Abstract][Full Text] [Related]
57. Antihypertensive mechanism of alacepril: effect on norepinephrine-induced vasoconstrictive response in vitro and in vivo.
Takeyama K; Minato H; Ikeno A; Hosoki K; Kadokawa T
Arzneimittelforschung; 1986; 36(1):74-7. PubMed ID: 3513780
[TBL] [Abstract][Full Text] [Related]
58. Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension.
Iimura O; Shimamoto K
J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S63-6. PubMed ID: 2474107
[TBL] [Abstract][Full Text] [Related]
59. Role of renin-angiotensin and kallikrein-kinin systems on the mechanism of the hypotensive effects of converting enzyme inhibitor, alacepril.
Tanaka S; Shimamoto K; Ando T; Nakahashi Y; Ura N; Hosoda S; Ishida H; Yamaji I; Yokoyama T; Masuda A
Clin Exp Hypertens A; 1987; 9(2-3):605-9. PubMed ID: 3038424
[TBL] [Abstract][Full Text] [Related]
60. Hypotensive effect of SA446, an angiotensin converting enzyme inhibitor, in 2-kidney, 1-clip renal hypertensive and normotensive dogs.
Nishimura K; Miyazaki M; Okunishi H; Toda N
Jpn J Pharmacol; 1987 Apr; 43(4):379-87. PubMed ID: 3039218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
